Iritec 40mg/2ml & 100mg/5ml injection Vial

Name Iritec
Description Irinotecan is a semisynthetic derivative of Camptothecin. It is an antineoplastic agent which acts as a specific inhibitor of type I DNA topoisomerase. It is metabolized by carboxylesterases in most tissues, thus yielding SN-38, which was found to be more active than Irinotecan on purified type I topoisomerase and more cytotoxic than Irinotecan against several human and murine tumour lines. Inhibition of type I DNA topoisomerase by Irinotecan or SN-38 induces lesions in the single-stranded DNA, and these lesions block DNA replication fork and are responsible for the cytotoxicity. This cytotoxic effect was found to be time dependent and S-phase specific.
Active Ingredient Irinotecan
Indication Irinotecan in combination therapy is indicated for the following cancer types:
  • Advanced colorectal cancer
  • Epidermal growth factor receptor (EGFR)
  • Metastatic carcinoma of the colon or rectum.
  • Metastatic colorectal carcinoma
Strengths 40mg/2ml & 100mg/5ml
Business Partner Vianex S.A
Origin Greece